Genetic pathways in colorectal cancer

Histopathology

Volumn 28, Issue 5, 1996, Pages 389-399

  Ilyas, M ^a   Tomlinson, I P M ^b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Adenoma carcinoma sequence; Colorectal cancer; Genetic pathways; Mutation selection

Indexed keywords

CANCER GENETICS; CARCINOGENESIS; COLORECTAL CANCER; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029936242     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.339381.x     Document Type: Review

References (114)

1. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol. Rev. 1993; 15; 499-545.
2. Toribara N, Sleisenger M. Screening for colorectal cancer. N. Engl. J. Med. 1995; 332; 861-867.
3. Tobi M, Luo FC, Ronai Z. Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J. Natl. Cancer Inst. 1994; 86; 1007-1010.
4. Sidransky D, Tokino T, Hamilton SR et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256; 102-105.
5. Wilson JM. Principles of screening for disease. Proc. R. Soc. Med. 1971; 64; 1255-1256.
6. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous sytem. Science 1993; 262; 695-700.
7. Raff MC. Cell death genes: Drosophila enters the field. Science 1994; 264; 668-669.
8. Bignami M, Rosa S, La-Rocca SA, Falcone G, Tato F. Differential influence of adjacent normal cells on the prolifertion of mammalian cells transformed by the viral oncogenes myc, ras and src. Oncogene 1988; 2; 509-514.
9. Raff MC. Social controls on cell survival and cell death. Nature 1992; 356; 397-400.
10. Peifer M. Cancer, catenins, and cuticle pattern: a complex connection. Science 1993; 262; 1667-1668.
11. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81; 495-504.
12. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995; 81; 479-482.
13. Del-Buono R, Pignatelli M, Bodmer WF, Wright NA. The role of the arginine-glycine-aspartic acid-directed cellular binding to type I collagen and rat mesenchymal cells in colorectal tumour differentiation. Differentiation 1991; 46; 97-103.
14. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989; 49; 3713-3721.
15. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304; 596-602.
16. Parada LF, Land H, Weinberg RH, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984; 312; 649-651.
17. Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 1992; 70; 153-161.
18. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36; 2251-2270.
19. Fearon ER, Vogelstein B. A genetic model for colorectal tumourigenesis. Cell 1990; 61; 759-767.
20. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359; 235-237.
21. Nakamura Y. The role of the adenomatous polyposis coli (APC) gene in human cancers. Adv. Cancer Res. 1993; 62; 65-87.
22. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992; 340; 626-630.
23. Phillips R, Spigelman A, Thompson J. Familial adenomatous polyposis and other polyposis syndromes. London: Edward Arnold, 1994.
24. Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling. J. Cell Biol. 1995; 128; 959-968.
25. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983; 11; 6883-6894.
26. Counts J, Goodman J. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 1995; 83; 13-15.
27. Bos JL. The ras gene family and human carcinogenesis. Mutat. Res. 1988; 195; 255-271.
28. Whetsell L, Maw G, Nadon N, Ringer DP, Schaefer FV. Polymerase chain reaction microanalysis of tumors from stained histological slides. Oncogene 1992; 7; 2355-2361.
29. Chaubert P, Benhattar J, Saraga E, Costa J. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am. J. Pathol. 1994; 144; 767-775.
30. Minamoto T, Yamashita N, Ochiai A et al. Mutant K-ras in apparently normal muscosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 1995; 75 (suppl.); 1520-1526.
31. Jen J, Powell SM, Papadopoulos N et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994; 54; 5523-5526.
32. Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. 1994; 8; 1174-1183.
33. Stallmach A, von-Lampe B, Orzechowski HD, Matthes H, Riecken EO. Increased fibronectin-receptor expression in colon carcinoma-derived HT 29 cells decreases tumorigenicity in nude mice. Gastroenterology 1994; 106; 19-27.
34. Pignatelli M, Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br. J. Cancer 1992; 66; 629-634.
35. Pignatelli M. Models of colorectal tumour differentiation. Cancer Surv. 1993; 16; 3-13.
36. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am. J. Pathol. 1993; 142; 981-986.
37. Donehower LA, Bradley A. The tumor suppressor p53. Biochim. Biophys. Acta 1993; 1155; 181-205.
38. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54; 4855-4878.
39. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358; 15-16.
40. el-Deiry WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994; 54; 1169-1174.
41. Cunningham C, Dunlop MG, Bird CC, Wyllie AH. Deletion analysis of chromosome 8p in sporadic colorectal adenomas. Br. J. Cancer 1994; 70; 18-20.
42. Kelemen PR, Yaremko ML, Kim AH, Montag A, Michelassi F, Westbrook CA. Loss of heterozygosity in 8p is assocated with microinvasion in colorectal carcinoma. Genes Chromosom. Cancer 1994; 11; 195-198.
43. Bravard A, Luccioni C, Muleris M, Lefrancois DBD. Relationships between umpk and pgd activities and deletions of chromosome 1p in colorectal cancers. Cancer Gent. Cytogenet. 1991; 56; 45-56.
44. Bardi G, Johansson B, Pandis N et al. Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathological features. Cancer 1993; 71; 306-314.
45. Atkin NB, Baker MC. Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet. Cytocgenet. 1993; 67; 123-125.
46. Zenklusen J, Thompson J, Kleinszanto A, Conti C. Frequent loss of heterozygosity in human primary squamous-cell and colon carcinomas at 7q32.I-evidence for a broad range tumor-suppressor gene. Cancer Res. 1995; 55; 1347-1350.
47. Young J, Leggett B, Ward M et al. Frequent loss of heterozygosity on chromosome-14 occurs in advanced colorectal carcinomas. Oncogene 1993; 8; 671-675.
48. Campo E, Miquel R, Jares P et al. Prognostic-significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. Cancer 1994; 73; 2913-2921.
49. Leggett B, Young J, Buttenshaw R et al. Colorectal carcinomas show frequent allelic loss on the long arm of chromosome-17 with evidence for a specific target region. B. J. Cancer 1995; 71; 1070-1073.
50. Purdie C, Piris J, Bird C, Wyllie A. 17q allele loss is associated with lymph-node metastasis in locally aggressive human colorectal-cancer. J. Pathol. 1995; 175; 297-302.
51. Iino H, Fukayama M, Maeda Y et al. Molecular genetics for clinical management of colorectal carcinoma. 17p. 18q. and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastic potential. Cancer 1994; 73; 1324-1331.
52. Yana I, Kurahashi H, Nakamori S et al. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers. Int. J. Cancer 1995; 60; 174-177.
53. Tanaka K, Yanoshita R, Konishi M et al. Suppression of tumorigenicity in human colon-carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 1993; 8; 2253-2258.
54. Imaseki H, Hayashi H, Taira M et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1989; 64; 704-709.
55. Matsumura T, Dohi K, Takanashi A, Ito H, Tahara E. Alteration and enhanced expression of the c-myc oncogene in human colorectal carcinomas. Pathol. Res. Pract. 1990; 186; 205-211.
56. Pavelic ZP, Pavelic L, Kuvelkar R, Gapany SR. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res. 1992; 12; 171-175.
57. Krisman MD, Scott JK, Astrin SM. Evidence that the familial adenomatous polyposis gene is involved in a subset of colon cancers with a complementable defect in c-myc regulation. Proc. Natal. Acad. Sci. USA 1989; 86; 4264-4268.
58. Vastrik I, Makela TP, Koskinen PJ Klefstrom J, Alitalo K. Myc protein: partners und antagonists. Crit. Rev. Oncog. 1994; 5; 59-68.
59. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994; 124; 1-6.
60. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359; 552-554.
61. Hauge A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994; 9; 3367-3370.
62. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumour progression model. Am. J. Pathol. 1995; 146; 20-26.
63. Peltomaki P. Microsatellite instability and Hereditary Non-Polyposis Colon Cancer. J. Pathol. 1995; 176; 329-330.
64. Watson P, Lynch H. The tumour spectrum in INPCC. Anticancer Res. 1994; 14; 1635-1640.
65. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260; 812-816.
66. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT. Pathology of hereditary Non-Polyposis Colorectal Cancer. Anticancer Res. 1994; 14; 1631-1634.
67. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260; 816-819.
68. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its associaton with hereditary nonpolyposis colon cancer. Cell 1993; 75; 1027-1038.
69. Peltomaki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260; 810-812.
70. Leach FS, Nicolaides NC, Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75; 1215-1225.
71. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368; 258-61.
72. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolypesis colon cancer. Nature 1994; 371; 75-80.
73. Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science 1994; 266; 1403-1405.
74. Kunkel TA. Nucleotide repeats. Slippery DNA and diseases. Nature 1993; 365; 207-208.
75. Modrich P. Mechanisms and biological effects of mismatch repair. Ann. Rev. Genet. 1991; 25; 229-253.
76. Fishel R, Kolodner RD. Identification of mismatch repir genes and their role in the development of cancer. Curr. Opin. Genet. Dev. 1995; 5; 382-395.
77. Radman M, Wagner R. Carcinogenesis. Missing mismatch repair. Nature 1993; 366; 722.
78. Parsons R, Li GM, Longley MJ et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75; 1227-1236.
79. Eshleman JR, Lang EZ, Bowerfind GK et al. Increased mutation rale at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 1995; 10; 33-37.
80. Aaltonen LA, Peltomaki P, Mecklin JP et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994; 54; 1645-1648.
81. Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 1995; 9; 48-55.
82. Jass JR, Stewart SM, Stewart J, Lane MR. Hereditary non-polyposis colon cancer - morphologies. genes and mutations. Mutat Res. 1994; 310; 125-133.
83. Jass JR. Colorectal adenomas in surgical specimens from subjects with hereditary non-polyposis colorectal cancer. Histopathology 1995; 27; 263-267.
84. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am. J. Pathol. 1994; 145; 148-156.
85. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268; 1336-1338.
86. Levin B. Inflammatory bowel disease and cancer. Cancer 1992; 70; 1313-1316.
87. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses A Jr., Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991; 32; 167-169.
88. Gyde S, Prior P, Allan R et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29; 206-217.
89. Morson B, Dawson I, Day D, Morson and Dawson's gastrointestinal pathology, third ed. Oxford: Blackwell Scientific Publications, 1990.
90. Connell W, Talbot IC, Harpaz N et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994; 35; 1419-1423.
91. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H-O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994; 107; 117-120.
92. Riddell R, Goldman H, Ransohoff D et al. Dysplasia in inflammatory bowel disease: standardised classification with provisional clinical applications. Hum. Pathol. 1993; 14; 931-968.
93. Richman PI, Tilly R, Jass JR, Bodmer WF. Colonic pericryptal fibroblast sheath cells: characterisation of cell type with a new monoclonal antibody. J. Clin. Pathol. 1987; 40; 593-600.
94. Yao T, Tsuneyoshi M. Significance of pericryptal fibroblasts in colorectal epithelial tumours: a special reference to the histologic features and growth patterns. Hum. Pathol. 1993; 24; 525-533.
95. Redston M, Papadopoulos N, Caldas C, Kinzler K, Kern S. Common occurrence of APC and K-ras mutation in the spectrum of colitis-associated neoplasias. Gastroenterology 1995; 108; 383-392.
96. Tarmin L, Yin J, Harpaz N, Kozam M et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995; 55; 2035-2038.
97. Bell SM, Kelly SA, Hoyle JA et al. C-ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br. J. Cancer 1991; 64; 174-178.
98. Meltzer SJ, Mane SM, Wood PK et al. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res. 1990; 50; 3627-3630.
99. Burmer GC, Levine DS, Kulander BG, Haggitt RC, Rubin CE, Rabinovitch PS. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990; 99; 416-420.
100. Fozard JB, Quirke P, Dixon, MF, Giles GR, Bird CC. DNA aneuploidy in ulcerative colitis. Gut 1986; 27; 1414-1418.
101. Melville DM, Jass JR, Shepherd NA et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988; 95; 668-675.
102. Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992; 102; 1149-1154.
103. Rubin CE, Haggit RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103; 1611-1620.
104. Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis. Colon Rectum 1994; 37; 313-319.
105. Yin J, Harpaz N, Tong Y et al. p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104; 1633-1639.
106. Brentall TA, Crispin DA, Rabinovitch PS et al. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107; 369-378.
107. Kuramoto S, Oohara T. Minute cancers arising de-nove in the human large intestine. Cancer 1988; 61; 829-834.
108. Yokota T, Sugihara K, Yokoyama T et al. Small depressed cancer of the large bowel: report of three cases. Am. J. Gastroenterol. 1995; 90; 134-136.
109. Yao T, Tada S, Tsuneyoshi M. Colorectal counterpart of gastric depressed adenoma. A comparison with flat and polypoid adenomas with special reference to the development of pericryptal fibroblasts. Am. J. Surg. Pathol 1994; 18; 559-568.
110. Yamagata S, Muto T, Uchida Y et al. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 1995; 75; 935-957.
111. Yukawa M, Fujimori T, Maeda S, Tabuchi M, Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 1994; 35; 1258-1261.
112. Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S. Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int. J. Cancer 1994; 57; 51-55.
113. Tada S, Yao T, Iida M, Koga H, Hizawa K, Fujishima M. A clinicopathologic study of small flat colorectal carcinoma. Cancer 1994; 74, 2430-2435.
114. Kuramoto S, Oohara T. How do colorectal cancers develop? Cancer 1995; 75 (suppl.); 1534-1538.